Celebrating World Water Day with a good WASH

Attribution:  Flickr, Diganta Talukdar

Attribution: Flickr, Diganta Talukdar

This coming Saturday marks the 22nd year that the United Nations General Assembly has recognized March 22nd as World Water Day. In observation of this special day, we would like to take a look back at a few of the articles PLOS Medicine, PLOS Neglected Tropical Diseases, and PLOS Pathogens have published on the importance of clean water to human health.
Continue reading »

Category: General, WASH | Tagged , | 1 Comment

Health in Jeopardy: the Corporate Influence on Climate Negotiations

Alicia Pawluk argues that United Nations climate policymakers should learn from the WHO Framework Convention on Tobacco Control and diminish the influence of fossil-fuel producers in climate talks.  

Image Credit: NOAA/NASA GOES Project

Image Credit: NOAA/NASA GOES Project

The health impacts of climate change will undoubtedly be the most pressing global health issue of the upcoming century. Rising sea levels, warmer global temperatures, and extreme weather events will all have a widespread global effect. International governmental measures must be taken to minimise the damage caused by these phenomena, and to mitigate future health disasters. The United Nations is striving towards global climate solutions but significant intrusions at international climate negotiations have hindered any progress.

Last year’s UN Climate Talks in Warsaw (Conference of Parties 19) set a new precedent for climate negotiations.  Unfortunately, instead of progressing towards global consensus on climate action, COP 19 stood out for more ominous reasons. Among the diplomats, climate scientists, and civil society participants was the overwhelming presence of fossil-fuel-intensive industries.  A majority of the sponsorship of the COP came from companies which benefit considerably from fossil-fuels, raising questions about the place of the fossil-fuel industry in climate negotiations.  The official corporate partners, including Alstom, the Polish fossil fuel companies PGE and LOTOS, ArcelorMittal, BMW, General Motors and Emirates Airlines, are hardly ‘leading the way’ on sustainability.
Continue reading »

Category: General | 1 Comment

Book Review: ‘Deadly Medicines and Organised Crime: How Big Pharma Has Corrupted Healthcare’ by Peter Gøtzsche

Tom Yates from University College London reviews Peter Gøtzsche’s recent book about the pharmaceutical industry.

Image credit: Sage Ross, Flickr

Image credit: Sage Ross, Flickr

I have long been concerned about the conduct of drug companies. I worry about pervasive conflict of interest in the generation, synthesis and dissemination of the evidence that guides my clinical practice. So, when I was asked to review Peter Gøtzsche’s book on these topics, I was excited.

It is hard to imagine someone better qualified to write this book: a biology and chemistry graduate, Peter Gøtzsche began his career as a sales rep for Astra. In 1977, he took responsibility for setting up a medical department at Astra-Syntex and saw from the inside how trials can be abused to build a case for particular products – in his case Naproxen, a non steroidal anti-inflammatory drug (NSAID). In 1978 he started medical school, whilst still working for the company, only leaving Astra-Syntex on qualification six years later.

Gøtzsche’s PhD focussed on bias in randomised controlled trials of NSAIDs for rheumatoid arthritis, generating important results regarding the impact of funding on outcome. He went on to help found the Cochrane Collaboration and to found the Nordic Cochrane Centre. His academic career has focussed on bias, trials and evidence synthesis.
Continue reading »

Category: Book Review, General | 4 Comments

Forced to Flee: Humanitarian Disasters Leave Women at Higher Risk

Tane Luna Ramirez from Médecins Sans Frontières reflects on the challenges of providing care for pregnant women as well as the heightened risk of sexual violence in disaster settings.

MSF is the main health care provider in Domeez refugee camp, Iraq, where more than 55,000 people, most from Syria, have settled.

MSF is the main health care provider in Domeez refugee camp, Iraq, where more than 55,000 people, most from Syria, have settled.
Photo credit: Pierre-Yves Bernard/MSF

Today, as International Women’s Day approaches, up to 23,000 people will be forced to flee their homes, joining 45 million others around the world who are already displaced due to conflict, persecution, or natural disaster. Of course people of both sexes suffer and die from the direct consequences of these displacements, and from the crises that cause them. But women are especially vulnerable. For those who are pregnant, lack of care may be their biggest threat to survival. And especially in contexts of conflict, women and girls face a hugely increased risk of sexual assault.
Continue reading »

Category: General | Tagged | Comments Off

Looking for $2 Trillion

The group of 20 (G20) finance ministers meeting in Australia has just announced an ambitious initiative to boost the world’s gross domestic product (GDP) by at least $2 trillion over the next five years.   To achieve this target they propose to shape and implement new policies that increase investment and employment, and promote competition and trade.

So far there has been no mention of health as a means to promote economic development among the G20 nations, even though we learned more than a decade ago from the World Health Organization’s Report of the Commission on Macroeconomics and Health led by Jeffrey Sachs that diseases can actually cause poverty. Such findings provided the basis for which disease targets were added to the Millennium Development Goals.

In an analysis published last year in PLOS NTDs I found a surprising number of neglected tropical diseases (NTDs) – a group of 17 major chronic, debilitating, and mostly parasitic infections – among the poor living in G20 countries.  Indeed most of the world’s cases of the worst NTDs (as measured in disability-adjusted life years) including Chagas disease, food-borne trematodiases, leishmaniasis, leprosy, lymphatic filariasis can be found G20 countries (together with Nigeria), as well as almost one-half of the hookworm cases.  Based on additional new data coming out of Oxford University, many of the world’s dengue fever cases are also among the G20.  So with the exception of a few NTDs such as African trypanosomiasis, onchocerciasis, and schistosomiasis, which are overwhelmingly sub-Saharan African diseases, the NTDs are mostly G20 problems.  This includes the United States where I have found widespread NTDs in the midst of southern poverty.

The poor living among the wealthy. Major areas of poverty in the G20 nations and Nigeria, where most of the world's NTDs occur (map prepared by Esther Inman). Figure from Hotez PJ (2013) NTDs V.2.0: “Blue Marble Health”—Neglected Tropical Disease Control and Elimination in a Shifting Health Policy Landscape. PLoS Negl Trop Dis 7(11): e2570. doi:10.1371/journal.pntd.0002570

The poor living among the wealthy. Major areas of poverty in the G20 nations and Nigeria, where most of the world’s NTDs occur (map prepared by Esther Inman). Figure from Hotez PJ (2013) NTDs V.2.0: “Blue Marble Health”—Neglected Tropical Disease Control and Elimination in a Shifting Health Policy Landscape. PLoS Negl Trop Dis 7(11): e2570. doi:10.1371/journal.pntd.0002570


Continue reading »

Category: General | Tagged , , , , , | Comments Off

Is Viral Load Testing for HIV a Realistic Strategy in Developing Countries?

Sara Gorman from Columbia University discusses viral load testing in resource-poor settings

Image Credit: David__Jones, Flickr

Image Credit: David_Jones, Flickr

In July of 2013, the World Health Organization (WHO) released new guidelines on antiretroviral therapy. Among the most significant new recommendations include: initiating ART earlier, in all individuals with a CD4 count of 500 per mm3 or less; starting ART at any CD4 count in particular populations, including pregnant and breastfeeding women and children under 5 years of age; and the use of viral load testing as the preferred method of monitoring response to ART and detecting treatment failure. Viral load measurement is already the method of choice for detecting treatment failure in high-income countries. But the recommendation has never included reliance on viral load measurement because middle- and low-income countries do not have the same access to the tools needed to measure viral load that high-income countries do. This raises an important question: are the new WHO recommendations realistic for low-income countries? If not, what needs to be done to achieve better access to technologies for viral load monitoring in resource-poor settings?

Viral load monitoring is often of critical importance to managing patients with HIV who take antiretrovirals. Viral replication in a patient taking ART can give rise to drug-resistant mutations as well as treatment failure. In addition, alternative drugs must be available in cases of treatment failure. If they are not, viral load testing to determine treatment failure is not useful.
Continue reading »

Category: General | 2 Comments

Vaccine Hesitancy: A Call for Papers from PLOS Currents: Outbreaks

PLOS Currents: Outbreaks issues a call for papers in collaboration with the European Centre for Disease Prevention and Control (ECDC) on the issue of vaccine hesitancy.

CurrentsPostcard-Outbreaks_finalThe prevention of outbreaks of vaccine-preventable diseases, such as measles, rubella, or polio, is dependent on herd immunity.  Yet ensuring widespread vaccination coverage is complicated by a wide range of factors, not least vaccine hesitancy, through which segments of the public are uncertain about the safety and efficacy of vaccinations.

In May 2013 the ECDC hosted a multi-disciplinary scoping meeting to address the issue of vaccine hesitancy. Participants came from the fields of psychology, anthropology, epidemiology and medicine to discuss trends in the public acceptance of vaccines, with the following objectives:

• to explore the key drivers behind recent trends in measles epidemiology and vaccination coverage in Europe

• to identify and conceptualize the myriad social and political factors that affect individual decision-making as concerns vaccination

• to identify and examine best practices in public health for monitoring and addressing public mistrust in vaccines

• to identify potential ECDC activities in this field
Continue reading »

Category: Collections, Vaccines | Tagged , , | Comments Off

Vaccine Hesitancy: A Call for Papers from PLOS Currents: Outbreaks

PLOS Currents: Outbreaks issues a call for papers in collaboration with the European Centre for Disease Prevention and Control (ECDC) on the issue of vaccine hesitancy.

CurrentsPostcard-Outbreaks_finalThe prevention of outbreaks of vaccine-preventable diseases, such as measles, rubella, or polio, is dependent on herd immunity.  Yet ensuring widespread vaccination coverage is complicated by a wide range of factors, not least vaccine hesitancy, through which segments of the public are uncertain about the safety and efficacy of vaccinations.

In May 2013 the ECDC hosted a multi-disciplinary scoping meeting to address the issue of vaccine hesitancy. Participants came from the fields of psychology, anthropology, epidemiology and medicine to discuss trends in the public acceptance of vaccines, with the following objectives:

• to explore the key drivers behind recent trends in measles epidemiology and vaccination coverage in Europe

• to identify and conceptualize the myriad social and political factors that affect individual decision-making as concerns vaccination

• to identify and examine best practices in public health for monitoring and addressing public mistrust in vaccines

• to identify potential ECDC activities in this field
Continue reading »

Category: Collections, Vaccines | Tagged , , | Comments Off

Drugs for the Poor, Drugs for the Rich: Why the Current R&D Model Doesn’t Deliver

Manica Balasegaram from the Médecins Sans Frontières (MSF) Access Campaign, reflects on a research and development system that is failing the world’s poorest people.

Image Credit: e-MagazineArt.com, Flickr

Image Credit: e-MagazineArt.com, Flickr

The past month has seen the reputation of Big Pharma dented more than usual. The CEO of German pharmaceutical company Bayer, Marijn Dekkers, was reported as saying that the company didn’t develop a cancer drug for the Indian market, but rather “for Western patients who can afford it”. The comment summed up the attitude of the pharmaceutical companies towards the poor and succinctly described what is wrong with today’s research and development (R&D) system.

In a similar vein, last month British/Swedish pharma company AstraZeneca announced it was pulling out of all early-stage R&D for malaria, tuberculosis (TB) and neglected tropical diseases – all diseases of the developing world. Instead, the company stated they will focus efforts on drugs for cancer, diabetes and high blood pressure, all diseases that affect rich countries, with potentially plenty of people to pay the high prices on new drugs.
Continue reading »

Category: General, MSF, Neglected Diseases | Tagged | 2 Comments

Drugs for the Poor, Drugs for the Rich: Why the Current R&D Model Doesn’t Deliver

Manica Balasegaram from the Médecins Sans Frontières (MSF) Access Campaign, reflects on a research and development system that is failing the world’s poorest people.

Image Credit: e-MagazineArt.com, Flickr

Image Credit: e-MagazineArt.com, Flickr

The past month has seen the reputation of Big Pharma dented more than usual. The CEO of German pharmaceutical company Bayer, Marijn Dekkers, was reported as saying that the company didn’t develop a cancer drug for the Indian market, but rather “for Western patients who can afford it”. The comment summed up the attitude of the pharmaceutical companies towards the poor and succinctly described what is wrong with today’s research and development (R&D) system.

In a similar vein, last month British/Swedish pharma company AstraZeneca announced it was pulling out of all early-stage R&D for malaria, tuberculosis (TB) and neglected tropical diseases – all diseases of the developing world. Instead, the company stated they will focus efforts on drugs for cancer, diabetes and high blood pressure, all diseases that affect rich countries, with potentially plenty of people to pay the high prices on new drugs.
Continue reading »

Category: General, MSF, Neglected Diseases | Tagged | 2 Comments